Diane Dragaud

April 19, 2023

Trial Results: ECOG-ACRIN Research Round-Up

Summaries of recently published ECOG-ACRIN research results
February 10, 2023

TMIST Passes 80,000 Patients Enrolled

Even as screening mammography volumes remain below pre-pandemic levels, TMIST continues to enroll women at a strong pace
February 10, 2023

Trial Results: ASH Highlights Practice-Changing Results for B-Lineage Acute Lymphoblastic Leukemia

The phase 3 E1910 clinical trial provides strong evidence for adding immunotherapy to standard front-line consolidation chemotherapy
February 10, 2023

Trial Results: ECOG-ACRIN Research Round-Up

Summaries of recently published ECOG-ACRIN research results
October 13, 2022

Trial Results: ECOG-ACRIN Completes the First Randomized Phase 3 Clinical Trial of Neoadjuvant Immunotherapy in Patients with Kidney Cancer

The phase III PROSPER RCC clinical trial demonstrated that priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma
October 13, 2022

Trial Results: ECOG-ACRIN Research Round-Up

Summaries of recently published ECOG-ACRIN research results
June 21, 2022

ECOG-ACRIN Names University of Pennsylvania’s Jennifer Eads As Its Young Investigator of the Year

The Group is recognizing Dr. Eads as an exceptional medical oncologist and committed educator who is making significant research contributions as an international disease expert in neuroendocrine tumors and gastroesophageal malignancies
June 21, 2022

ECOG-ACRIN Research at ASCO 2022

ECOG-ACRIN researchers presented a wide range of study results at the 2022 ASCO Annual Meeting
April 15, 2022

Now Enrolling: ECOG-ACRIN Opens a New NCI-MATCH Treatment Arm for dMMR and LAG-3-Positive Cancers as it Continues to Locate Patients with BRAF Mutations

The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.
April 15, 2022

Enrollment in TMIST Breast Cancer Screening Trial Surpasses Halfway Mark; Recruitment of Women from Diverse Backgrounds is Key to Success

Enrollment doubles in past 17 months due to specific efforts — Black participation rises above 20%
April 15, 2022

NCI-MATCH: The Blueprint for Future Precision Medicine Trials

In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.
February 24, 2022

Trial Results: Copanlisib in Patients with PIK3CA-Mutated Tumors

The first published results of a platform trial of PIK3CA mutations across multiple tumor types appear in the Journal of Clinical Oncology. The data are from the NCI-MATCH precision medicine trial.